Belgian Biotech Grows its Pipeline of Immuno-Oncology Therapies

Oncurious has licensed five immuno-oncology candidates developed at VIB to expand its pipeline of cancer therapies.

The young Belgian biotech Oncurious has decided to step up its game through an agreement with the Vlaams Institute for Biotechnology (VIB) in Flanders that gives it exclusive licenses to five next-generation immunotherapy candidates. In exchange, the VIB is increasing its shares in the company and will receive royalties on future sales of the drugs. ThromboGenics, the main shareholder, will chip in with an additional €2.1M.

The new candidates will be an addition to Oncurious’ lead program, TB-403, currently in Phase I/IIa trials for medulloblastoma, a form of brain cancer that accounts for 20% of brain tumors in children. The experimental therapy consists of a monoclonal antibody against placental growth factor (PlGF) with potential to become the first targeted therapy to treat medulloblastoma.


Image via Bika Ambon / Shutterstock

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.

We use cookies to give you the best experience. If you click on accept, we also use tracking cookies for analytics and advertising purposes. Check our privacy policy for more details. By accepting, you support our independent media and its’ freely accessible content. You may withdraw your consent at any time.